SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CDT

CDT Equity Inc. (NASDAQ:CDT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.23-$0.04 (-13.89%)
 
Market cap
$107K
Insider Score
Health Score
Listed since
Mar 28, 2022
Market Cap$107.21K-100.0%
Revenue (ttm)$1.45B
Net Income$93.66M+561.2%
EPS$200.92+97.4%
Shares Out466.14K
PE Ratio0.00
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume836,680
Open$0.24
Previous Close$0.27
Day's Range$0.22 - $0.24
52-Week Range$0.22 - $291250.00
Beta1.69
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CDT

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Address
4581 Tamiami Trail North, Naples, FL, 34103, US
Market Cap
0 million
Employees
4
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$7.30K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From CDT’s reported statements · Q3 2026 (trailing 12 months)
1 Day
-13.89%
5 Days
-44.68%
1 Month
-92.04%
6 Months
-100.00%
1 Year
-100.00%

$CDT stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CDT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CDT's directors and management

Net Shares Purchased by Insiders−3M−1.5M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CDT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CDT Revenue by Segment or Geography

CDT's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CDT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CDT from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from CDT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
0
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
4
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.